| Dr Lucinda T Patton, MD | |
|
1700 Springhill Ave, Suite 100, Mobile, AL 36604-1407 | |
| (251) 435-1200 | |
| (251) 435-6357 |
| Full Name | Dr Lucinda T Patton |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 28 Years |
| Location | 1700 Springhill Ave, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942246467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | 24354 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mobile Infirmary Medical Center | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Imc-diagnostic And Medical Clinic Llc | 2860399623 | 135 |
News Archive
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.
People with learning (intellectual) disabilities have historically been marginalised from mainstream society, and have had limited choice and control over their lives. While movements to achieve greater equality have had success, the rapid advancement of modern technology risks creating a new form of digital exclusion.
Among Asian/Pacific Islander women living in the United States, those who reside in ethnic enclaves-areas with a high concentration of residents of a similar ancestry-are less likely to have pregnancy or birth complications than those living in other areas, suggests a study by researchers at the National Institutes of Health and other institutions.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Infants in special care baby units or neonatal intensive care units are at greater risk for missed or incomplete newborn screening than normal newborns. To minimize the risk of missing or delaying a diagnosis, Clinical and Laboratory Standards Institute (CLSI) recently published a new document, "Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline" (I/LA31-A).
› Verified 1 days ago
| Entity Name | Imc-diagnostic And Medical Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447201066 PECOS PAC ID: 2860399623 Enrollment ID: O20031218000577 |
News Archive
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.
People with learning (intellectual) disabilities have historically been marginalised from mainstream society, and have had limited choice and control over their lives. While movements to achieve greater equality have had success, the rapid advancement of modern technology risks creating a new form of digital exclusion.
Among Asian/Pacific Islander women living in the United States, those who reside in ethnic enclaves-areas with a high concentration of residents of a similar ancestry-are less likely to have pregnancy or birth complications than those living in other areas, suggests a study by researchers at the National Institutes of Health and other institutions.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Infants in special care baby units or neonatal intensive care units are at greater risk for missed or incomplete newborn screening than normal newborns. To minimize the risk of missing or delaying a diagnosis, Clinical and Laboratory Standards Institute (CLSI) recently published a new document, "Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline" (I/LA31-A).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucinda T Patton, MD 1700 Springhill Ave, Suite 100, Mobile, AL 36604-1407 Ph: (251) 435-1200 | Dr Lucinda T Patton, MD 1700 Springhill Ave, Suite 100, Mobile, AL 36604-1407 Ph: (251) 435-1200 |
News Archive
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.
People with learning (intellectual) disabilities have historically been marginalised from mainstream society, and have had limited choice and control over their lives. While movements to achieve greater equality have had success, the rapid advancement of modern technology risks creating a new form of digital exclusion.
Among Asian/Pacific Islander women living in the United States, those who reside in ethnic enclaves-areas with a high concentration of residents of a similar ancestry-are less likely to have pregnancy or birth complications than those living in other areas, suggests a study by researchers at the National Institutes of Health and other institutions.
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
Infants in special care baby units or neonatal intensive care units are at greater risk for missed or incomplete newborn screening than normal newborns. To minimize the risk of missing or delaying a diagnosis, Clinical and Laboratory Standards Institute (CLSI) recently published a new document, "Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline" (I/LA31-A).
› Verified 1 days ago
Dr. Leonard Joseph Caputo, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 548 Boulevard Park W, B, Mobile, AL 36609 Phone: 251-304-0042 Fax: 251-304-0262 | |
Dr. Alma M Herrera, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 101 Memorial Hospital Dr, Suite 299, Mobile, AL 36608 Phone: 251-414-5900 Fax: 251-281-1169 |